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Introduction
Exciting new advances have occurred in the field of
hematopoietic transplantation biology in the last two
decades. More powerful reagents and techniques for
classification of HLA antigens to match donors and recip-
ients, new conditioning regimens to prepare recipients
for transplantation and new methods of transplantation
(autologous transplantation, cord blood and stem cell
transplantation) are in use. Also, entirely new concepts
about graft versus malignancy reactions have come from
data collected over years of experience with transplanta-
tion in humans and in valuable mouse models. However,
graft versus host disease (GVHD) continues to be a
major complication of hematopoietic cell transplantation,
occurring in 30-80 percent of recipients. The concept of
GVHD was first formulated by Rupert Billingham [1]. It
occurs when “the graft contains immunologically compe-
tent cells, the recipient expresses tissue antigens that
are not present in the transplant donor, and the recipient
is incapable of mounting an effective response to destroy
the transplanted cells” [2]. We know now that the media-
tors of GVHD are dendritic cells, T cells, NK cells,
macrophages, cytokines and surface markers on
immune cells (major and minor histocompatibility
antigens, MHC and MiHC respectively) in the recipient.
The recipient is usually immunocompromised either
chemically by irradiation and chemotherapy or physio-
logically, as in neonates. Risks for developing GVHD
include donor-recipient gender mismatch, HLA
mismatch, older age of recipient, high numbers of T cells
transfused from donor, host exposure to previous blood
product transfusion, and low concentrations of immuno-
suppressants in recipient (Table I). The combination of
immunocompromise due to conditioning regimen, slow
recovery of the transplanted immune system and
immunosuppression for GVHD all contribute to
increased susceptibility of recipients to life-threatening
infections and mortality due to bone marrow failure.
This review focuses on emerging concepts of GVHD,
the different manifestations of GVHD, the treatment of
GVHD and new transplantation regimens. We will
concentrate on cutaneous manifestations and therapies
that dermatologists would encounter. Most importantly,
new information gained through advances in transplan-
tation biology has contributed to our rapidly increasing
fund of knowledge about the immune system.
Emerging concepts of graft versus host
disease.
Types of GVHD
Acute GVHD Clinical. Acute GVHD can occur within
the first weeks after transplantation, with greater
frequency and severity for HLA nonidentical or unrelated
donors. The clinical manifestations include “dermatitis,
hepatitis, and enteritis”, which reflect injury to epithelia
by activated immune cells. There is also injury to the
immune system itself, leading to increased susceptibility
to infection. Skin is an early target (Table II). GVHD
usually begins on the palms, soles, ears, and oral
mucosa. In acute GVHD, skin findings generally precede
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Table I.
Risks for Graft versus Host Disease
• Donor-recipient gender mismatch
• Histocompatibility antigen mismatch
(major and minor)
• Older age of recipient
• Host exposure to previous blood product
transfusion
• High numbers of T cells in the donor inoculum
• Low concentrations of immunosuppressants
in recipient
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liver and gastrointestinal tract involvement. Tender
erythematous macules are seen first. These are often
folliculocentric, reflecting injury to hair follicle epithelium
as well as epidermis. The macules may coalesce into
confluent erythema, and in severe cases, subepidermal
bullae can form with blistering. A fulminant form evolving
into a lichen planus-like dermatitis can be seen. Acute
GVHD is graded according to a system that includes
percentage of total skin that is inflamed, amount of
diarrhea per 24 hours, and serum level of bilirubin. The
clinical differential diagnosis is drug eruption, viral
exanthem, subacute radiation dermatitis, cutaneous
reaction of lymphocyte recovery, and in severe cases,
erythema multiforme and toxic epidermal necrolysis.
Histopathology. Interface dermatitis with epidermal
injury out of proportion to the inflammation is the key to
cutaneous and mucosal GVHD (Figure 1A, B). Hair folli-
cle and eccrine duct involvement and location of apoptot-
ic cells in suprabasilar keratinocyte layer are also helpful
in making the diagnosis of GVHD. Apoptosis is the
mechanism of keratinocyte death in human and mouse
GVHD[3, 4]. The histologic differential diagnosis is usual-
ly drug eruption. A definitive diagnosis of GVHD versus
hypersensitivity reaction is controversial. Using the
classic criteria (apoptotic keratinocytes in epidermis and
appendages, basal cell vacuolization, satellitosis) inves-
tigators in a correlative study found that no single or
combined feature above could predict clinical GVHD [5].
Nevertheless, dermatopathologists are still asked to
make the call if possible because of the devastating
consequences of not recognizing early GVHD.
Treatment. The standard treatment for acute GVHD
is prophylaxis with cyclosporin A and methotrexate, and
methyl prednisone for approximately 2 weeks, with a
glucocorticoid taper if GVHD manifestations are resolv-
ing. However, glucocorticoids fail to control GVHD in a
large number of patients (up to 80% of transplanted
patients in some early studies)[6]. This is an urgent
problem which is addressed with a line of secondary
therapies including polyclonal anti-thymus globulin
(ATG), mega-dose glucocorticoids in the ranges of 5-20
milligrams/kg/day, macrolides such as tacrolimus and
sirolimus, mycophenolic acid, and exciting new
monoclonal antibodies to a variety of immune cell
surface markers and to cytokine receptors[7-9]. PUVA
(psoralen plus UVA light) is effective for steroid-resistant
acute GVHD of the skin[10]. Extracorporeal photophere-
sis has also been used successfully[11, 12].
Chronic GVHD Clinical. Chronic GVHD is distin-
guished from acute GVHD by clinical symptoms that can
resemble an overlap of several connective tissue
diseases (lupus erythematosus, mixed connective tissue
disease, scleroderma, Sjogren syndrome, biliary cirrho-
sis, idiopathic pulmonary fibrosis). The classical defini-
tion of chronic GVHD is GVHD that persists or occurs de
novo beyond 80-100 days post BMT. Chronic GVHD
occurs in approximately 30 to 60% of patients, particu-
larly when hematopoietic stem cells are used instead of
bone marrow, and when the donor is not an HLA identi-
cal sibling[6]. In limited chronic GVHD, mild skin involve-
ment, mild involvement of ocular, oral, or vaginal
mucosa, and small changes in liver function tests are
seen. Systemic therapy is usually not used for these
individuals. In severe chronic GVHD, degree of epithelial
involvement is more extensive, leading to serositis,
hepatitis, biliary cirrhosis, severe gastrointestinal injury,
and bronchiolitis obliterans. Individuals with chronic
GVHD can develop alopecia and pigmentary changes,
and are more susceptible to skin cancers, and to
cutaneous viral and fungal infections (herpes, mollus-
cum, candida, and opportunistic deep fungi)(Table II).
Jaundice is a late occurrence. In chronic GVHD,
lichenoid papules resembling lichen planus in flexural
surfaces (lichenoid GVHD) and white mucosal patches
occur. In some patients (approximately 15 %) scleroder-
matous plaques are present (sclerodermatous graft
versus host disease), with esophageal dysmotility, skin
fibrosis, and joint contractures[13]. A polymyositis-like
disorder with muscle weakness, pain, and necrotic
muscle fibers on biopsy can occur in small numbers (less
than 1%) of individuals with chronic GVHD[14]. Sicca
syndrome is common. Individuals with chronic GVHD
can develop autoantibodies to nuclear antigens similar to
those in autoimmune diseases[15]. When extensive skin
involvement, thrombocytopenia and progressive type
onset are present, non-relapse mortality is high[16].
Histology. The histology of chronic cutaneous GVHD
can be lupus-like or scleroderma-like. In the lichenoid
form, chronic-interface dermatitis leads to sawtoothing of
epidermal rete and hyperkeratosis (Figure 1C, D). In the
sclerodermoid form, dermal fibrosis begins in the papil-
lary dermis and extends to subcutaneous fat. Ultimately
sclerotic collagen and adnexal atrophy are seen
(Figure 1E, F).
Treatment. Treatment of severe chronic GVHD has
historically been with early administration of long-term
glucocorticoids and cyclosporin or tacrolimus. Many of
the immunomodulatory agents mentioned above are
also useful in chronic GVHD, including thalidomide and
etretinate[8]. Of note are some interesting studies with
Table II.
Cutaneous and mucosal manifestations
of GVHD
Acute GVHD
• Macular erythema with pruritus first on
palms, soles, ears and oral mucosa
• May progress to confluent erythema with
blistering if severe
• Bacterial, viral and fungal infections
• Oral: lacy patches in oral mucosa
Chronic GVHD
• Lichenoid papules in flexures
(lichenoid variant)
• Sclerodermatous plaques and joint
contractures (sclerodermoid variant)
• Bacterial, viral and fungal infections
• Hyperkeratosis
• Alopecia
• Pigmentary changes, mottling
• Onychodystrophy
• Oral: xerostomia, mucositis, ulceration,
lichen planus-like changes
252 GILLIAM THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
extracorporeal photopheresis, in which a significant
number of patients improve clinically[11, 12]. Supportive
care includes artificial tears for ocular dryness,
pilocarpine for xerostomia, and nutritional supplements
for severe mucositis. Anti-osteoporosis regimens are
helpful to decrease bone loss from long term corticos-
teroid therapy. Overall, the best treatment for chronic
GVHD is prevention.
Transfusion associated GVHD. This is a rare and
usually fatal complication of transfusion with blood
products, including red blood cells, platelet concentrates,
fresh plasma and granular cell concentrations. It results
when donor and recipient share HLA haplotypes, and
can occur when donations are obtained from first or
second-degree relatives or from populations with a
restricted pool of HLA haplotypes. Transfusion associat-
ed GVHD can also occur when the recipient has deficient
cell mediated immunity, either inherited, as in severe
combined immunodeficiency, or acquired, as in
Figure 1
A, B: Acute cytotoxic GVHD in skin. In A (low power), an
acute interface process involving epidermis is present, with
“injury out of proportion to inflammation”. In B, mononuclear
cells tag early apoptotic keratinocytes mainly in the basilar
keratinocyte area.
C, D: Chronic lichenoid GVHD in mucosa. In C (low power)
mucosa is thickened and hyperplastic, with a band-like
lichenoid inflammatory infiltrate in submucosa. Some
“sawtoothing” of the epithelium is present. In B (high power),
the dramatic infiltration of lower epithelium by mononuclear
cells is seen.
E, F: Chronic sclerodermoid GVHD in skin. In E (low power),
dense acellular collagen is present at all levels of dermis, but
more prominently in upper dermis. In F (high power), the
thick collagen bundles are more apparent. No dramatic
interface changes are seen as in acute or chronic
cytotoxic GVHD.
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Hodgkin's disease. Clinical manifestations include a
subtle skin rash, fever, diarrhea, hepatic dysfunction,
and acute bone marrow failure approximately 1 to 2
weeks after transfusion. Transfusion associated GVHD
is prevented by giving blood products that are previous-
ly treated with gamma irradiation. Treatment is usually
not effective in severe disease[17].
Syngeneic GVHD. A rare and unexpected variant of
graft versus host disease can occur with identical twin-
twin transplantation, despite the identical genetic compo-
sition of donor and recipient. This is also the form of
GVHD that occurs in autologous hematopoietic cell
transplantation (transplantation with an individual’s own
hematopoietic cells). Syngeneic GVHD can be modeled
in inbred strains of mice. It is thought that self-tolerance
is lost in the setting of an irradiated thymus and
cyclosporin or IFN-gamma administered during recovery
of the transplanted immune system.
Graft versus malignancy reaction. One of the most
important observations to come from transplantation
biology for hematopoietic malignancies is that trans-
planted individuals with GVHD appear to have a lower
rate of relapse of their malignancy than individuals
without GVHD. It is thought that the donor lymphocytes
attack not only host target tissues (skin, liver, gut), but
also residual host malignant cells. This is been designat-
ed the “graft versus malignancy” or “graft versus
leukemia” effect. Supporting this hypothesis is the obser-
vation that relapsed individuals can return to remission
after another infusion of donor lymphocytes. Therefore
the trend in recent years has been to achieve a delicate
balance with less intensive and non-myeloblative condi-
tioning and sufficient immunosuppression to maintain the
engraftment and hematopoiesis in order to enhance the
graft versus malignancy effect.
Another advance using graft versus malignancy
effect has been the use of hematopoietic stem cell trans-
plantation in non-myeloblative regimens for solid tumors
such as melanoma, and for carcinoma of ovary, lung,
colon, kidney, prostate, and breast[18].
Methods of transplantation determine different forms
and severity of GVHD.
Allogeneic bone marrow transplantation (BMT)
(transplantation of bone marrow from one genetically
unique individual to another unique individual). The
prototypic transplantation scenario in the past has been
of bone marrow from one sibling to the other. In this
situation, major histocompatibility antigens (HLA) are
most easily matched because of close genetic identity of
the two individuals. Nevertheless, a perfect HLA match
does not prevent GVHD because other genetic systems
are also involved. The minor histocompatibility antigens
(MiHC) are less well understood and characterized and
can differ between siblings. There are also genetically
determined polymorphisms of genes for cytokines,
chemokines, and molecules of the innate immune
system which recognize bacteria and viruses that may
be important. This area of investigation is a newly
emerging one with great promise for the future. Better
methods of genetic and immunologic matching will
continue to improve the survival of transplanted
individuals.
Hematopoietic stem cell transplantation (HSC). This
method of transplantation has been used for approxi-
mately a decade. HSC has been a great improvement
because the transplant infusion material can be enriched
for CD34-positive hematopoietic stem cells. This allows
transplantation of fewer cells, and more rapid recovery of
the recipient immune system. The risk for GHVD is
thought to be higher with stem cell transplantation,
however.
Cord blood transplantation. A recent development in
transplantation involves the use of immune cells in
neonatal cord blood from placenta[19, 20]. Because the
neonatal immune system is immature (naive), it is possi-
ble to transplant across large disparities in HLA antigens
without causing severe GVHD. This remarkable proper-
ty of cord blood enlarges the numbers of potential donors
for transplantation. The downside of cord blood trans-
plantation is that the transplanted immune system
remains immature for a long period of time (up to 18
months), making the recipient highly susceptible to
fungal and viral infections.
Non-myeloblative stem cell transplantation for human
solid tumors. Incomplete immune ablation is a recent
development in transplantation that avoids the known
deleterious effects of intense conditioning x-ray and
chemotherapy regimens. It adds to the beneficial effects
of graft versus malignancy reaction in which residual
malignant cells can be eliminated by the transplanted
immune cells. Although still in its infancy, this area holds
promise for older patients who cannot undergo intensive
conditioning and those with highly immunogenic tumors
such as renal cell carcinoma. However, no benefits have
been demonstrated for patients with extensive metastat-
ic disease[18], and the results with melanoma, breast,
ovarian, prostate carcinoma, to name a few, are still very
preliminary. Life-threatening acute GVHD can still occur
with nonmyeloablative transplantation. Older patients
who develop severe GVHD after nonmyeloablative
transplantation are also more likely to die of GVHD than
younger ones[21].
Why does GVHD occur? 
GVHD results from transplanting cells from individu-
als that are genetically different in cell surface molecules
called histocompatibility antigens. The histocompatibility
antigens were first identified in rodents as antigens
responsible for rejection of tissue grafts between differ-
ent strains of animals. Human major histocompatibility
complex (MHC) genes encode antigens for tissue typing,
many of which are involved in the steps leading to T cell
activation. They lie on the short arm of chromosome 6
called the HLA (human leukocyte antigen) region and
are designated MHC I and II. MHC Class I and Class II
antigens are usually typed by molecular methods now,
replacing the earlier serologic or cellular typing
techniques. The average patient has approximately a 20
to 30 percent chance of having an HLA match within his
immediate family. These numbers are higher for individ-
uals from Japan with less genetic diversity, and lower for
individuals of African descent with more polymorphisms
than most other racial groups. Minor histocompatibility
antigens (MiHC) are also important in GVHD but are less
well understood and characterized. Depending on the
degree of MHC and MiHC mismatch and the presence of
certain critical genetic differences in donor and recipient,
GVHD can occur.
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Ferrara et al.[22, 23] have proposed a 3 phase model
of GVHD (Table III): (1) The conditioning regimen, with
high dose radiation and chemotherapy causes injury to
the gut and other tissues, and release of inflammatory
cytokines such as tumor necrosis factor alpha 
(TNF-alpha), interferon-gamma (IFN-gamma), inter-
leukin 2 (IL-2) and interleukin 12 (IL-12). These changes
promote activation of host antigen presenting cells
(APCs) (2) Donor cell activation and expansion. Donor T
cells recognize foreign recipient antigens presented by
activated host APCs. Under the influence of altered
cytokine environments, autoreactive T cells proliferate.
(3) Target tissue injury. Self-reactive T cells then activate
macrophages and natural killer cells which along with the
T cells secrete additional cytokines that damage host
tissue. NK cells and cytotoxic T cells attack keratinocytes
directly.
The skin, liver and mucosa as target organs of
GVHD. All these targets of injury in GVHD are “barrier
epithelia” which can respond rapidly to external insults
with inflammation. Increased chemokines, cytokines,
and antigen presenting capacity by dendritic cells may
predispose the barrier organs to GVHD after conditioning
that leads to enhanced nonspecific inflammation and
tissue damage. One possible scenario is that gut injury
allows leakage of LPS via gut flora into the bloodstream,
leading to cytokine release, particularly TNF-alpha, a
major cytokine of GVHD which can induce keratinocyte
apoptosis. The specific molecules targeted in GVHD are
not known, but are assumed to be cell surface molecules
unique to epithelial cells. In skin, suprabasilar
keratinocytes express VCAM-1 and keratin 15 and may
be a target for injury[24, 25]. Therefore, damage to skin
results from a combination of “cytokine storm”, and direct
cytotoxic T cell and NK cell injury to keratinocytes
(satellite cell necrosis).
Types of cells that mediate GVHD that can trigger
keratinocyte apoptosis(26).
Donor cells. Both CD4-positive and CD8-positive T
cells can induce GVHD in murine disease, depending on
the histocompatibility mismatch. CD56-positive NK cells
have also been shown to play a role not only in direct
cytotoxic injury to epithelia but also in engraftment and
graft versus malignancy effects. T regulatory cells that
are CD4-positive CD25-negative may also be important.
Recipient cells. Host dendritic cells (DCs) are critical
to the development of GVHD (27). DCs from old mice
express more TNF-alpha and IL- 12, and stimulate better
allo-reactions than DCs from young mice, possibly
explaining the higher risk of severe GVHD in older
patients[28]. Lastly, expression of MHC molecules on
host DCs only and not on epithelial cells is sufficient to
initiate GVHD[29].
Cytokines, chemokines and growth factors of GVHD.
The Th1 cytokines predominate in classic cytotoxic
GVHD. TNF-alpha, IFN-gamma and IL-2 are major
cytokines that are increased in serum of patients with
GVHD. TNF-alpha can cause apoptosis of cells directly;
IFN-gamma can cause upregulation of MHC and costim-
ulatory molecules on APCs and enhance Fas-mediated
apoptosis. Keratinocyte growth factor can downregulate
TNF-alpha and IFN-gamma and has a protective effect
on GI epithelium, decreasing GVHD in a murine
model[29]. Chemokines play a critical role in recruitment
of leukocytes to target tissues.
In autologous/syngeneic GVHD, autoreactive CD8+ T
cells recognize MHC class II antigens in the setting of
markedly elevated IL-10 and MIP-1 alpha mRNA levels
by PBMCs in patients. Patients predisposed to develop
autologous/syngeneic GVHD have IL-10(-1082) G/G
polymorphic alleles that determine increased baseline
IL-10 production(30), a possible explanation for their
susceptibility to syngeneic/autologous GVHD.
In sclerodermatous GHVD, where disease is charac-
terized by skin and visceral fibrosis rather than epithelial
injury, increased production of TGF-beta by T cells and
monocyte/macrophages leads to upregulated collagen
synthesis in a murine model[31]. The cytokine profile in
sclerodermatous GVHD is mixed, but is Th2-predomi-
nant. CD4+ T cells are increased in early disease and
activated monocyte/macrophages appear to play an
important role in pathogenesis[32].
These are areas of active investigation, in which
researchers are testing novel immunomodulatory
molecules in mouse models for GVHD. The goal is to
develop more specific and targeted interventions that will
decrease GVHD, preserve graft versus malignancy
effect, and decrease the risk of infection that occurs with
systemic immunosuppression.
Summary
Graft versus host disease is a potentially devastating
consequence of hematopoietic transplantation that is
immunologically mediated. Several variant forms exist
(acute, chronic lichenoid, chronic sclerodermoid,
transfusion-related, autologous/syngeneic). GVHD
results from attack of transplanted donor lymphocytes on
host tissues when histocompatibility and immunologic
Table III.
Three Phase Model of Acute GVHD [22, 23]
1. The conditioning regimen with XRT and
chemotherapy produces host tissue injury
a. Chemokines and cytokines are
released
b. Host dendritic cells in spleen and
peripheral target tissues (skin, liver,
gut) are activated
2. Donor T cells are activated by dendritic
cells and proliferate
a. More chemokines and cytokines are
released and expansion of autoreac-
tive T cells occurs
b. Nonspecific downstream effector cells
such as NK cells and monocyte/
macrophages are activated
3. Target tissue injury occurs
a. Keratinocytes die by apoptosis in skin,
liver and gut via “cytokine storm” and
direct injury (satellite cell necrosis)
b. Autoreactive donor T cells attack the
remaining host immune system
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differences exist between donor and recipient (allogene-
ic transplantation), and when recovery of the immune
system occurs in the setting of damaged thymus and
cyclosporin administration (syngeneic/autologous trans-
plantation). Skin is a major target organ, along with gut
and liver. A plausible hypothesis for GVHD is that condi-
tioning with XRT and chemotherapy before transplanta-
tion damages tissue, causing release of cytokines and
chemokines and causing nonspecific inflammation in the
“barrier epithelia” that interface with the outside environ-
ment. Host antigen presenting cells in these sites are
activated, and then interact with donor lymphocytes
brought to the area by the inflammation. The donor
lymphocytes proliferate and trigger downstream events
(more cytokine secretion, activation of macrophages and
NK cells). Damage to epithelia of skin, gut and liver
follows via direct cytotoxic injury and via cytokines that
cause keratinocyte apoptosis. Mouse models for GVHD
have been invaluable in dissecting out the critical
pathways in GVHD and in testing new interventions to
prevent and treat GVHD.
In the past, therapy has been with potent nonspecific
immunosuppressants. More recently, exciting new more
focused therapies (immunomodulatory molecules and
antibodies to immune cell markers, PUVA, extracorpore-
al photopheresis) have been developed and are increas-
ingly useful for GVHD.
REFERENCES
1. Billingham, R. E. 1966. The biology of graft
versus host disease. Harvey Lectures 62:21.
2. Ferrara, J. L., and H. J. Deeg. 1991. Graft-
versus-host disease. New England Journal of
Medicine 324:667.
3. Gilliam, A. C., D. Whitaker-Menezes, R.
Korngold, and G. F. Murphy. 1996. Apoptosis
is the predominant form of epithelial target cell
injury in acute experimental graft-versus-host
disease. Journal of Investigative Dermatology
107:377.
4. Langley, R. G., N. Walsh, T. Nevill, L. Thomas,
and G. Rowden. 1996. Apoptosis is the mode
of keratinocyte death in cutaneous graft-
versus-host disease. Journal of the American
Academy of Dermatology 35:187.
5. Kohler, S., M. R. Hendrickson, N. J. Chao, and
B. R. Smoller. 1997. Value of skin biopsies in
assessing prognosis and progression of acute
graft-versus-host disease. American Journal of
Surgical Pathology 21:988.
6. Carpenter, P. A., and J. E. Sanders. 2003.
Steroid-refractory graft-vs.-host disease: past,
present and future. Pediatric Transplantation 7
Suppl 3:19.
7. Bruner, R. J., and S. S. Farag. 2003.
Monoclonal antibodies for the prevention and
treatment of graft-versus-host disease.
Seminars in Oncology 30:509.
8. Dean, R. M., and M. R. Bishop. 2003. Graft-
versus-host disease: emerging concepts in
prevention and therapy. Current Hematology
Reports 2:287.
9. Davies, J. K., and M. W. Lowdell. 2003. New
advances in acute graft versus host disease
prophylaxis. Transfusion Medicine 13:387.
10. Furlong, T., W. Leisenring, R. Storb, C.
Anasetti, F. R. Appelbaum, P. A. Carpenter, H.
J. Deeg, K. Doney, H. P. Kiem, R. A. Nash, J.
E. Sanders, R. Witherspoon, D. Thompson,
and P. J. Martin. 2002. Psoralen and ultraviolet
A irradiation (PUVA) as therapy for steroid-
resistant cutaneous acute graft-versus-host
disease. Biology of Blood & Marrow Trans-
plantation 8:206.
11. Greinix, H. T., B. Volc-Platzer, W. Rabitsch, B.
Gmeinhart, C. Guevara-Pineda, P. Kalhs, J.
Krutmann, H. Honigsmann, M. Ciovica, and R.
M. Knobler. 1998. Successful use of extracor-
poreal photochemotherapy in the treatment of
severe acute and chronic graft-versus-host
disease. Blood 92:3098.
12. Zic, J. A., J. L. Miller, G. P. Stricklin, and L. E.
King, Jr. 1999. The North American experience
with photopheresis. Therapeutic Apheresis 3:50.
13. Penas, P. F., M. Jones-Caballero, M. Aragues,
J. Fernandez-Herrera, J. Fraga, and A. Garcia-
Diez. 2002. Sclerodermatous graft-vs-host
disease: clinical and pathological study of 17
patients. Archives of Dermatology 138:924.
14. Stevens, A. M., K. M. Sullivan, and J. L.
Nelson. 2003. Polymyositis as a manifestation
of chronic graft-versus-host disease. Rheuma-
tology 42:34.
15. Rouquette-Gally, A. M., D. Boyeldieu, A. C.
Prost, and E. Gluckman. 1988. Autoimmunity
after allogeneic bone marrow transplantation.
A study of 53 long-term-surviving patients.
Transplantation 46:238.
16. Akpek, G., S. J. Lee, M. E. Flowers, S. Z.
Pavletic, M. Arora, S. Lee, S. Piantadosi, K. A.
Guthrie, J. C. Lynch, A. Takatu, M. M.
Horowitz, J. H. Antin, D. J. Weisdorf, P. J.
Martin, and G. B. Vogelsang. 2003. Perfor-
mance of a new clinical grading system for
chronic graft-versus-host disease: a multicen-
ter study. Blood 102:802.
17. Pamphilon, D. 2002. Transfusion-associated
graft versus host disease. http://www.blood.co.
uk/hospitals/guidelines/pdf/GvHD.pdf.
18. Renga, M., P. Pedrazzoli, and S. Siena. 2003.
Present results and perspectives of allogeneic
non-myeloablative hematopoietic stem cell
transplantation for treatment of human solid
tumors. Annals of Oncology 14:1177.
256 GILLIAM THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
19. Isoyama, K., K. Ohnuma, K. Kato, T. A.
Takahashi, S. Kai, S. Kato, M. Takanashi, N.
Sato, H. Sato, K. Kitajima, T. Naoe, H. Saito, H.
Nishihira, and N. Japanese Cord Blood Bank.
2003. Cord blood transplantation from unrelat-
ed donors: a preliminary report from the Japan-
ese Cord Blood Bank Network. Leukemia &
Lymphoma 44:429.
20. Laughlin, M. J., J. Barker, B. Bambach, O. N.
Koc, D. A. Rizzieri, J. E. Wagner, S. L. Gerson,
H. M. Lazarus, M. Cairo, C. E. Stevens, P.
Rubinstein, and J. Kurtzberg. 2001.
Hematopoietic engraftment and survival in
adult recipients of umbilical-cord blood from
unrelated donors. New England Journal of
Medicine 344:1815.
21. Anagnostopoulos, A., and S. Giralt. 2002. Criti-
cal review on non-myeloablative stem cell
transplantation. Crit Rev Onc/Hematol 44:175.
22. Teshima, T., and J. L. Ferrara. 2002. Under-
standing the alloresponse: new approaches to
graft-versus-host disease prevention. Sem-
inars in Hematology 39:15.
23. Ferrara, J. L. 2000. Pathogenesis of acute
graft-versus-host disease: cytokines and cellu-
lar effectors. Journal of Hematotherapy & Stem
Cell Research 9:299.
24. Kim, J. C., D. Whitaker-Menezes, M. Deguchi,
B. S. Adair, R. Korngold, and G. F. Murphy.
2002. Novel expression of vascular cell
adhesion molecule-1 (CD106) by squamous
epithelium in experimental acute graft-versus-
host disease. American Journal of Pathology
161:763.
25. Whitaker, D., S. C. Jones, T. M. Friedman, R.
Korngold, and G. F. Murphy. 2003. An epithe-
lial target site in experimental graft versus host
disease and cytokine-mediated cytotoxicity is
defined by cytokeratin 15. Biol Blood Marrow
Transplant 9:559.
26. Vogelsang, G. B., L. Lee, and D. M. Bensen-
Kennedy. 2003. Pathogenesis and treatment of
graft-versus-host disease after bone marrow
transplant. Annual Review of Medicine 54:29.
27. Schlomchik, W. D., M. S. Couzens, C. B. Tang,
J. McNiff, M. E. Robert, J. Liu, M. J. Shlomchik,
and S. G. Emerson. 1999. Prevention of graft
versus host disease by inactivation of host
antigen-presenting cells. Science 285:412.
28. Ordemann, R., R. Hutchinson, J. Friedman, S.
J. Burakoff, P. Reddy, U. Duffner, T. M. Braun,
C. Liu, T. Teshima, and J. L. Ferrara. 2002.
Enhanced allostimulatory activity of host
antigen-presenting cells in old mice intensifies
acute graft-versus-host disease. Journal of
Clinical Investigation 109:1249.
29. Teshima, T., R. Ordemann, P. Reddy, S.
Gagin, C. Liu, K. R. Cooke, and J. L. Ferrara.
2002. Acute graft-versus-host disease does
not require alloantigen expression on host
epithelium.[see comment][erratum appears in
Nat Med 2002 Sep;8(9):1039]. Nature
Medicine 8:575.
30. Hess, A. D., and C. J. Thoburn. 1997. Immuno-
biology and immunotherapeutic implications of
syngeneic/autologous graft-versus-host dis-
ease. Immunological Reviews 157:111.
31. McCormick, L. L., Y. Zhang, E. Tootell, and A.
C. Gilliam. 1999. Anti-TGF-beta treatment
prevents skin and lung fibrosis in murine
sclerodermatous graft-versus-host disease: a
model for human scleroderma. Journal of
Immunology 163:5693.
32. Zhang, Y., L. L. McCormick, S. R. Desai, C.
Wu, and A. C. Gilliam. 2002. Murine scleroder-
matous graft-versus-host disease, a model for
human scleroderma: cutaneous cytokines,
chemokines, and immune cell activation.
Journal of Immunology 168:3088.
UPDATE ON GRAFT VERSUS HOST DISEASE 257123 : 2 AUGUST 2004
